Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fudan University: Clinical Trials & FDA Approval Profile

Fudan University (Global / Institutional) sponsors 571 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 352 active protocols (200 recruiting now), 31 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.4%
Median Closed Enrollment vs National (145 pts)49 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fudan University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)571
Active Pipeline (Recruiting Now)352 (200)
Completed vs Stopped Early31 / 8 (1.4%)
Median Closed Actual Enrollment49 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fudan University
Hospital Research SiteLocationShared Protocols
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality276
Zhongshan Hospital Fudan UniversityShanghai20

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fudan University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05909332Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)Phase IIIRECRUITING
NCT05891093Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)Phase IIIRECRUITING
NCT07362810G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell TransplantationPhase IIRECRUITING
NCT06521866Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Fudan University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI